EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Clinical Characteristics, Diagnosis, and Treatment of Thyroid Stimulating Hormone-Secreting Pituitary Neuroendocrine Tumor (TSH PitNET): A Single-Center Experience

Jung Heo, Yeon-Lim Suh, Se Hoon Kim, Doo-Sik Kong, Do-Hyun Nam, Won-Jae Lee, Sung Tae Kim, Sang Duk Hong, Sujin Ryu, You-Bin Lee, Gyuri Kim, Sang-Man Jin und 2 weitere

Endocrinology and Metabolism · 2024

DOI: 10.3803/enm.2023.1877 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Endocrinology and Metabolism, 2024. Verfasst von Jung Heo und 13 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology and Metabolism, Department of Internal Medicine, Myongji Hospital, Hanyang University College of Medicine, Goyang, Korea. Hauptthemen laut MEDLINE: Thyrotropin, Pituitary Neoplasms, Neuroendocrine Tumors. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Thyroid-stimulating hormone (TSH)-secreting pituitary neuroendocrine tumor (TSH PitNET) is a rare subtype of PitNET. We investigated the comprehensive characteristics and outcomes of TSH PitNET cases from a single medical center. Also, we compared diagnostic methods to determine which showed superior sensitivity.

Methods

A total of 17 patients diagnosed with TSH PitNET after surgery between 2002 and 2022 in Samsung Medical Center was retrospectively reviewed. Data on comprehensive characteristics and treatment outcomes were collected. The sensitivities of diagnostic methods were compared.

Results

Seven were male (41%), and the median age at diagnosis was 42 years (range, 21 to 65); the median follow-up duration was 37.4 months. The most common (59%) initial presentation was hyperthyroidism-related symptoms. Hormonal co-secretion was present in four (23%) patients. Elevated serum alpha-subunit (α-SU) showed the greatest diagnostic sensitivity (91%), followed by blunted response at thyrotropin-releasing hormone (TRH) stimulation (80%) and elevated sex hormone binding globulin (63%). Fourteen (82%) patients had macroadenoma, and a specimen of one patient with heavy calcification was negative for TSH. Among 15 patients who were followed up for more than 6 months, 10 (67%) achieved hormonal and structural remission within 6 months postoperatively. A case of growth hormone (GH)/TSH/prolactin (PRL) co-secreting mixed gangliocytoma-pituitary adenoma (MGPA) was discovered.

Conclusion

The majority of the TSH PitNET cases was macroadenoma, and 23% showed hormone co-secretion. A rare case of GH/TSH/PRL co-secreting MGPA was discovered. Serum α-SU and TRH stimulation tests showed great diagnostic sensitivity. Careful consideration is needed in diagnosing TSH PitNET. Achieving remission requires complete tumor resection. In case of nonremission, radiotherapy or medical therapy can improve the long-term remission rate.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ThyrotropinPituitary NeoplasmsNeuroendocrine TumorsHumansMaleFemaleMiddle AgedAdultRetrospective StudiesAgedYoung AdultFollow-Up StudiesTreatment Outcome

Stichwörter der Autor:innen

Central hyperthyroidismMixed gangliocytoma pituitary adenomaPituitary neuroendocrine tumorThyrotropin-secreting pituitary neuroendocrine tumoralpha-Subunit

Substanzen

Thyrotropin

Autor:innen und Institutionen

  • Division of Endocrinology and Metabolism, Department of Internal Medicine, Myongji Hospital, Hanyang University College of Medicine, Goyang, Korea.
  • Department of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
  • Department of Pathology, Yonsei University College of Medicine, Seoul, Korea.
  • Department of Neurosurgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
  • Department of Radiology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
  • Department of Otorhinolaryngology-Head and Neck Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

Zitieren

APA

Heo, J., Suh, Y. L., Kim, S. H., Kong, D. S., Nam, D. H., Lee, W. J., Kim, S. T., Hong, S. D., Ryu, S., Lee, Y. B., Kim, G., Jin, S. M., Kim, J. H., & Hur, K. Y. (2024). Clinical Characteristics, Diagnosis, and Treatment of Thyroid Stimulating Hormone-Secreting Pituitary Neuroendocrine Tumor (TSH PitNET): A Single-Center Experience. Endocrinology and Metabolism. https://doi.org/10.3803/enm.2023.1877

Vancouver

Heo J, Suh YL, Kim SH, Kong DS, Nam DH, Lee WJ, et al. Clinical Characteristics, Diagnosis, and Treatment of Thyroid Stimulating Hormone-Secreting Pituitary Neuroendocrine Tumor (TSH PitNET): A Single-Center Experience. Endocrinology and Metabolism. 2024. doi:10.3803/enm.2023.1877

BibTeX
@article{Heo2024,
  author = {Heo, Jung and Suh, Yeon-Lim and Kim, Se Hoon and Kong, Doo-Sik and Nam, Do-Hyun and Lee, Won-Jae and Kim, Sung Tae and Hong, Sang Duk and Ryu, Sujin and Lee, You-Bin and Kim, Gyuri and Jin, Sang-Man and Kim, Jae Hyeon and Hur, Kyu Yeon},
  title = {Clinical Characteristics, Diagnosis, and Treatment of Thyroid Stimulating Hormone-Secreting Pituitary Neuroendocrine Tumor (TSH PitNET): A Single-Center Experience},
  journal = {Endocrinology and Metabolism},
  year = {2024},
  doi = {10.3803/enm.2023.1877}
}
Kostenlos starten →